mouse monoclonal anti glun2b (NeuroMab)
Structured Review
Mouse Monoclonal Anti Glun2b, supplied by NeuroMab, used in various techniques. Bioz Stars score: 94/100, based on 55 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti-glun2b+antibody/Anti-GluN2B-NR2B+Glutamate+Receptor+Antibody/pmc12882719-316-9-11
Average 94 stars, based on 55 article reviews
Images
Related Articles
Incubation:Article Title: A GluN2B disease-associated variant promotes the degradation of NMDA receptors via autophagy Article Snippet: Cell lysates (1000 μg) were pre-cleared with 30 μl of Protein A/G plus-agarose beads (Santa Cruz Biotechnology, sc-2003) and 1 μg normal mouse IgG (Santa Cruz Biotechnology, #sc-2025) for 1 h at 4 °C to remove nonspecific binding proteins. .. The pre-cleared lysates were incubated with 2 μg of Article Title: A GluN2B disease-associated variant promotes the degradation of NMDA receptors via autophagy. Article Snippet: Cell lysates (1000 μg) were pre-cleared with 30 μL of Protein A/G plus-agarose beads (Santa Cruz Biotechnology, sc-2003) and 1 μg normal mouse IgG (Santa Cruz Biotechnology, #sc-2025) for 1 hr at 4°C to remove nonspecific binding proteins. .. The pre-cleared lysates were incubated with 2 μg of Article Title: A GluN2B disease-associated variant promotes the degradation of NMDA receptors via autophagy Article Snippet: .. The cells were then incubated with 3% BSA containing Article Title: A GluN2B disease-associated variant promotes the degradation of NMDA receptors via autophagy. Article Snippet: .. The cells were then incubated with 3% BSA containing Membrane:Article Title: Alterations of NMDAR Subunits in the Cerebrospinal Fluid Across Neurodegenerative and Immunological Disorders Article Snippet: .. Then, the membrane was blocked with Odyssey Blocking Buffer for 1 h. Primary antibodies were used against GluN2B C‐terminal (mouse, 1:800 antibody dilution, Invitrogen MA1‐2014), GluN2B N‐terminal (rabbit, 1:800, Alomone AGC‐003), Blocking Assay:Article Title: Alterations of NMDAR Subunits in the Cerebrospinal Fluid Across Neurodegenerative and Immunological Disorders Article Snippet: .. Then, the membrane was blocked with Odyssey Blocking Buffer for 1 h. Primary antibodies were used against GluN2B C‐terminal (mouse, 1:800 antibody dilution, Invitrogen MA1‐2014), GluN2B N‐terminal (rabbit, 1:800, Alomone AGC‐003), Cell-Signaling:Article Title: Alterations of NMDAR Subunits in the Cerebrospinal Fluid Across Neurodegenerative and Immunological Disorders Article Snippet: .. Then, the membrane was blocked with Odyssey Blocking Buffer for 1 h. Primary antibodies were used against GluN2B C‐terminal (mouse, 1:800 antibody dilution, Invitrogen MA1‐2014), GluN2B N‐terminal (rabbit, 1:800, Alomone AGC‐003), other:Article Title: A GluN2B disease-associated variant promotes the degradation of NMDA receptors via autophagy. Article Snippet: The rabbit monoclonal anti-GluN2B antibody (#ab183942, RRID:AB_2889878, 1:3000), rabbit polyclonal anti-GluN2B (#ab73001, RRID:AB_1269571, 1:300), and rabbit monoclonal anti-Na+/K+ ATPase antibody (#ab76020, RRID:AB_1310695, 1:20,000;1:300) were purchased from Abcam. Article Title: A GluN2B disease-associated variant promotes the degradation of NMDA receptors via autophagy Article Snippet: The |
![Expression of GluN2A (A) and <t>GluN2B</t> (B) and basal extracellular levels of L‐glutamate (C) and D‐serine (D) in 4‐weeks and 8‐weeks of age S286L‐TG and wild‐type littermate. Ordinates indicate mean ± SD ( n = 6) of (A) expression levels of GluN2A relative to GAPDH in the plasma membrane fraction (B) expression levels of GluN2B relative to GAPDH in the plasma membrane fraction, (C) basal extracellular L‐glutamate level (μM) and (D) basal extracellular D‐serine level (μM) in the frontal cortex of wild‐type (gray column) and S286L‐TG (blue column). The lower‐side panels in A and B indicate pseudo‐gel images of capillary immunoblotting. Circles indicate the values of each individual rat. * p < 0.05, relative to 4‐weeks of age (4 W) and # p < 0.05 relative to wild‐type using two‐way ANOVA with Scheffe's post hoc test. F ‐values were in (A) expression of GluN2A ( F age [1, 20] = 46.7 [ p < 0.05], F genotype [1, 20] = 5.34 [ p < 0.05], F age*genotype [1, 20] = 1.1 [ p > 0.05]), (B) expression of GluN2B ( F age [1, 20] = 22.4 [ p < 0.05], F genotype [1, 20] = 8.3 [ p < 0.05], F age*genotype [1, 20] = 2.0 [ p > 0.05]), (C) L‐glutamate level ( F age [1, 20] = 3.2 [ p > 0.05], F genotype [1, 20] = 21.2 [ p < 0.05], F age*genotype [1, 20] = 1.9 [ p > 0.05]) and (D) D‐serine level ( F age [1, 20] = 8.4 [ p < 0.05], F genotype [1, 20] = 21.6 [ p < 0.05], F age*genotype [1, 20] = 2.8 [ p > 0.05]).](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_9079/pmc13109079/pmc13109079__PRP2-14-e70256-g002.jpg)
